Matches in SemOpenAlex for { <https://semopenalex.org/work/W1601065475> ?p ?o ?g. }
- W1601065475 endingPage "3840" @default.
- W1601065475 startingPage "3831" @default.
- W1601065475 abstract "We compared the safety and immunogenicity of the recombinant Plasmodium falciparum MSP1(42) antigen formulated with four novel adjuvant systems (AS01B, AS02A, AS05 and AS08) to alum in rhesus monkeys. All five formulations of MSP1(42) were safe and immunogenic. Whereas, all MSP1(42) formulations tested generated high stimulation indices for lymphocyte proliferation (ranging from 27 to 50), the AS02A and AS01B formulations induced the highest levels of specific anti-MSP1(42) antibody. ELISPOT assays showed that the AS02A and AS01B vaccine formulations-induced different cytokine response profiles. Using the ratio of IFN-gamma/IL-5 secreting cells as the metric, the AS01B formulation induced a strong Th1 response, whereas the AS02A formulation induced a balanced Th1/Th2 response. The IFN-gamma response generated by AS02A and AS01B formulations persisted at least 24 weeks after final vaccination. The notable difference in Th1/Th2 polarization induced by the AS02A and AS01B formulations warrants comparative clinical testing." @default.
- W1601065475 created "2016-06-24" @default.
- W1601065475 creator A5013809378 @default.
- W1601065475 creator A5015438763 @default.
- W1601065475 creator A5016697483 @default.
- W1601065475 creator A5023513706 @default.
- W1601065475 creator A5040634125 @default.
- W1601065475 creator A5052679483 @default.
- W1601065475 creator A5055911118 @default.
- W1601065475 creator A5063817027 @default.
- W1601065475 creator A5064528399 @default.
- W1601065475 creator A5068844838 @default.
- W1601065475 creator A5077029331 @default.
- W1601065475 creator A5080329476 @default.
- W1601065475 creator A5084564556 @default.
- W1601065475 creator A5087806737 @default.
- W1601065475 date "2004-09-28" @default.
- W1601065475 modified "2023-10-06" @default.
- W1601065475 title "Pre-clinical evaluation of the malaria vaccine candidate . MSP1 formulated with novel adjuvants or with alum" @default.
- W1601065475 cites W1534267102 @default.
- W1601065475 cites W1588700076 @default.
- W1601065475 cites W1610017743 @default.
- W1601065475 cites W1661544713 @default.
- W1601065475 cites W1813288331 @default.
- W1601065475 cites W1903803599 @default.
- W1601065475 cites W1962127316 @default.
- W1601065475 cites W1971148645 @default.
- W1601065475 cites W1979071257 @default.
- W1601065475 cites W1984303903 @default.
- W1601065475 cites W1984830230 @default.
- W1601065475 cites W1986315531 @default.
- W1601065475 cites W1990223878 @default.
- W1601065475 cites W1996674616 @default.
- W1601065475 cites W1999070120 @default.
- W1601065475 cites W2010895610 @default.
- W1601065475 cites W2036875255 @default.
- W1601065475 cites W2038322646 @default.
- W1601065475 cites W2044470177 @default.
- W1601065475 cites W2049580315 @default.
- W1601065475 cites W2058371986 @default.
- W1601065475 cites W2058412182 @default.
- W1601065475 cites W2062278593 @default.
- W1601065475 cites W2067620951 @default.
- W1601065475 cites W2069469281 @default.
- W1601065475 cites W2074122062 @default.
- W1601065475 cites W2080843329 @default.
- W1601065475 cites W2086747066 @default.
- W1601065475 cites W2092924223 @default.
- W1601065475 cites W2097169724 @default.
- W1601065475 cites W2101847661 @default.
- W1601065475 cites W2103426586 @default.
- W1601065475 cites W2105920586 @default.
- W1601065475 cites W2109985559 @default.
- W1601065475 cites W2110134485 @default.
- W1601065475 cites W2111695773 @default.
- W1601065475 cites W2127179292 @default.
- W1601065475 cites W2127357344 @default.
- W1601065475 cites W2134881135 @default.
- W1601065475 cites W2142004326 @default.
- W1601065475 cites W2145464179 @default.
- W1601065475 cites W2154374820 @default.
- W1601065475 cites W2155144810 @default.
- W1601065475 cites W2161149598 @default.
- W1601065475 cites W2162134485 @default.
- W1601065475 cites W2164209355 @default.
- W1601065475 cites W2170736102 @default.
- W1601065475 cites W2171988175 @default.
- W1601065475 cites W2177327503 @default.
- W1601065475 cites W2187965615 @default.
- W1601065475 cites W2208001051 @default.
- W1601065475 cites W2340524139 @default.
- W1601065475 cites W2394668152 @default.
- W1601065475 cites W2415797677 @default.
- W1601065475 cites W2465639432 @default.
- W1601065475 cites W609901129 @default.
- W1601065475 doi "https://doi.org/10.1016/j.vaccine.2004.07.023" @default.
- W1601065475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15364429" @default.
- W1601065475 hasPublicationYear "2004" @default.
- W1601065475 type Work @default.
- W1601065475 sameAs 1601065475 @default.
- W1601065475 citedByCount "64" @default.
- W1601065475 countsByYear W16010654752012 @default.
- W1601065475 countsByYear W16010654752013 @default.
- W1601065475 countsByYear W16010654752014 @default.
- W1601065475 countsByYear W16010654752015 @default.
- W1601065475 countsByYear W16010654752016 @default.
- W1601065475 countsByYear W16010654752019 @default.
- W1601065475 countsByYear W16010654752021 @default.
- W1601065475 crossrefType "journal-article" @default.
- W1601065475 hasAuthorship W1601065475A5013809378 @default.
- W1601065475 hasAuthorship W1601065475A5015438763 @default.
- W1601065475 hasAuthorship W1601065475A5016697483 @default.
- W1601065475 hasAuthorship W1601065475A5023513706 @default.
- W1601065475 hasAuthorship W1601065475A5040634125 @default.
- W1601065475 hasAuthorship W1601065475A5052679483 @default.
- W1601065475 hasAuthorship W1601065475A5055911118 @default.
- W1601065475 hasAuthorship W1601065475A5063817027 @default.
- W1601065475 hasAuthorship W1601065475A5064528399 @default.